What about stroke or pain?

Stroke reports leave important gaps

Reports from Russian stroke studies described quicker recovery in groups that had Semax alongside their usual treatment.

A 1997 report included 30 people given Semax and a usual-care comparison group of 80.

A 2018 study had 110 people in total.

An abstract is a short summary of a study. These summaries were available in English; the full Russian papers were not read for this guide.

Neither summary said people were put into treatment groups by chance or that patients and staff were kept unaware of who received Semax.

Choosing groups by chance helps make a fair comparison. Keeping the treatment secret during a study helps stop people’s hopes from shaping what they report or measure.

Without those details, the reports cannot show that Semax caused the faster recovery.

The pain study was also limited

The Food and Drug Administration, or FDA, found a small study with no comparison group for migraine and severe facial nerve pain.

Most of the migraine group still had pain afterwards, while the facial nerve pain group showed no change.

Without a comparison, it is hard to separate a treatment effect from what might have happened anyway.

The FDA conclusion

The FDA found too little evidence of benefit for Semax in brain injury from poor blood flow, migraine or severe facial nerve pain.

Its review also notes that FDA-approved treatments exist for those conditions, as checked September 30, 2026.

A visit can start with what care is already available for the condition, and why a different approach is being discussed. Ask how the proposed option compares.